Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks (Nasdaq: ZYME), a clinical-stage biotechnology company focused on developing multifunctional biotherapeutics for cancer, inflammation, and autoimmune diseases, has announced its participation in three major upcoming investor conferences in February 2025.
The company will be present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, participating in one-on-one meetings and a fireside chat at 11:20 am ET. Management will also join Citi's 2025 Virtual Oncology Leadership Summit for a virtual fireside chat on February 20 at 2:00 pm ET. Additionally, they will attend the B. Riley Securities Precision Oncology & Radiopharma Conference in New York on February 28, engaging in one-on-one meetings and a panel discussion.
Zymeworks (Nasdaq: ZYME), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di bioterapeutiche multifunzionali per il cancro, l'infiammazione e le malattie autoimmuni, ha annunciato la sua partecipazione a tre importanti conferenze per investitori in programma per febbraio 2025.
L'azienda sarà presente alla 35ª Conferenza Annuale Oppenheimer sulle Scienze della Vita e della Salute l'11 febbraio, partecipando a incontri one-to-one e a una chiacchierata informale alle 11:20 ora ET. La direzione parteciperà anche al Summit Virtuale di Leadership Oncologica Citi 2025 per una chiacchierata virtuale il 20 febbraio alle 14:00 ora ET. Inoltre, parteciperanno alla Conferenza sulla Oncologia di Precisione & Radioterapia di B. Riley Securities a New York il 28 febbraio, impegnandosi in incontri one-to-one e in una discussione di gruppo.
Zymeworks (Nasdaq: ZYME), una empresa biotecnológica en etapa clínica centrada en desarrollar bioterapéuticos multifuncionales para el cáncer, la inflamación y enfermedades autoinmunes, ha anunciado su participación en tres importantes conferencias de inversores programadas para febrero de 2025.
La compañía estará presente en la 35ª Conferencia Anual Oppenheimer de Ciencias de la Salud el 11 de febrero, participando en reuniones uno a uno y en una charla informal a las 11:20 a.m. ET. La dirección también se unirá al Summit Virtual de Liderazgo Oncológico Citi 2025 para una charla virtual el 20 de febrero a las 2:00 p.m. ET. Además, asistirán a la Conferencia sobre Oncología de Precisión y Radioterapia de B. Riley Securities en Nueva York el 28 de febrero, participando en reuniones uno a uno y en una discusión de panel.
Zymeworks (Nasdaq: ZYME)는 암, 염증 및 자가면역 질환을 위한 다기능 생물치료제를 개발하는 데 초점을 맞춘 임상 단계의 생명공학 회사로, 2025년 2월에 예정된 주요 투자자 회의에 세 번 참가할 것이라고 발표했습니다.
회사는 2월 11일 Oppenheimer 제35회 연례 헬스케어 생명과학 회의에 참여하여 1:1 미팅 및 오후 11:20 ET에 열리는 화기애애한 대화에 참석할 예정입니다. 경영진은 2월 20일 오후 2:00 ET에 열리는 Citi 2025년 가상 종양학 리더십 서밋에도 함께하여 가상 논의에 참여합니다. 또한, 이들은 2월 28일 뉴욕에서 열리는 B. Riley Securities 정밀 종양학 및 방사선 의약품 회의에 참석하여 1:1 미팅 및 패널 토론에 참여할 것입니다.
Zymeworks (Nasdaq: ZYME), une société de biotechnologie en phase clinique spécialisée dans le développement de biothérapeutiques multifonctionnels pour le cancer, l'inflammation et les maladies auto-immunes, a annoncé sa participation à trois grandes conférences pour investisseurs prévues en février 2025.
L'entreprise sera présente à la 35e Conférence Annuelle Oppenheimer sur les Sciences de la Vie et de la Santé le 11 février, participant à des réunions en tête-à-tête et à un échange informel à 11h20 ET. La direction participera également au Sommet Virtuel de Leadership Oncologique de Citi 2025 pour une discussion virtuelle le 20 février à 14h00 ET. De plus, ils assisteront à la Conférence sur l'Oncologie de Précision et la Radiopharmacie de B. Riley Securities à New York le 28 février, s'engageant dans des réunions en tête-à-tête et une discussion de panel.
Zymeworks (Nasdaq: ZYME), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung multifunktionaler Biotherapeutika für Krebs, Entzündungen und Autoimmunerkrankungen konzentriert, hat seine Teilnahme an drei wichtigen bevorstehenden Investorenkonferenzen im Februar 2025 bekannt gegeben.
Das Unternehmen wird am 11. Februar an der 35. Jahrestagung von Oppenheimer zu Gesundheit und Lebenswissenschaften teilnehmen und an persönlichen Gesprächen sowie einem informellen Gespräch um 11:20 Uhr ET teilnehmen. Das Management wird auch an dem virtuellen Onkologie-Führungsgipfel von Citi 2025 teilnehmen, um am 20. Februar um 14:00 Uhr ET ein virtuelles Gespräch zu führen. Darüber hinaus werden sie am 28. Februar an der B. Riley Securities Konferenz für präzise Onkologie & Radiopharma in New York teilnehmen und in persönlichen Gesprächen sowie einer Podiumsdiskussion engagieren.
- None.
- None.
VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences:
- Oppenheimer 35th Annual Healthcare Life Sciences Conference: Zymeworks’ management will participate in virtual one-on-one meetings and a fireside chat on February 11 at 11:20 am Eastern Time (ET).
- Citi's 2025 Virtual Oncology Leadership Summit: Zymeworks’ management will participate in a virtual fireside chat on February 20 at 2:00 pm ET.
- B. Riley Securities Precision Oncology & Radiopharma Conference: Zymeworks’ management will participate in one-on-one meetings and a panel discussion on February 28 in New York, NY.
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz Pharmaceuticals), granting each exclusive rights to develop and commercialize zanidatamab in different territories. The U.S. FDA granted accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) second-line biliary tract cancer (BTC). Ziihera® is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. Zanidatamab is currently under regulatory review in the EU and China for second-line BTC and is being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with investigational new drug applications for ZW220 and ZW251 planned for 2025. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
FAQ
What investor conferences will ZYME participate in during February 2025?
When is Zymeworks' presentation at the Oppenheimer Healthcare Conference 2025?
What type of meetings will ZYME hold at the B. Riley Securities Conference?
What is the timing of ZYME's fireside chat at Citi's 2025 Virtual Oncology Summit?
